IRLAB Therapeutics AB is dedicated to improving the lives of patients suffering from neurological disorders. The company focuses on developing innovative pharmaceuticals that target unmet medical needs, particularly within the field of Parkinson's disease. IRLAB Therapeutics AB's core values include a commitment to scientific excellence, collaboration, and a patient-centered approach. By combining cutting-edge research with a deep understanding of the complexities of neurological disorders, IRLAB Therapeutics AB strives to bring transformative treatments to market and make a positive impact on the lives of those affected by these conditions.

IRLAB Therapeutics AB is primarily present in Sweden, where it is headquartered.

IRLAB Therapeutics AB has achieved several significant milestones in its corporate journey. In recent years, the company has made remarkable progress in the field of neurological disorders. IRLAB successfully completed a Phase 2b study for its candidate, IRL752, intended for the treatment of Parkinson's disease psychosis. The positive results demonstrated the drug's potential in addressing this challenging condition. Additionally, IRLAB advanced its Phase 2a study for IRL790, a drug candidate targeting Parkinson's disease symptoms, such as abnormal involuntary movements. The company's commitment to innovative therapies and dedication to improving patients' lives showcases IRLAB Therapeutics AB as a leading player in the neurology sector.

IRLAB Therapeutics AB is a pharmaceutical company based in Sweden. It was founded in 2012 with a focus on developing innovative treatments for neurodegenerative diseases and Parkinson's disease. IRLAB Therapeutics AB is dedicated to improving the quality of life for patients affected by these conditions. The company's research and development efforts are centered around exploring new drug candidates and therapeutic solutions. IRLAB Therapeutics AB aims to address the unmet medical needs in neurology and create effective medications that can significantly impact patients' lives. With a strong commitment to scientific excellence, IRLAB Therapeutics AB is actively pursuing advancements in the field of neurodegenerative diseases.

The main competitors of IRLAB Therapeutics AB in the market are pharmaceutical companies that focus on developing therapeutics for neurological disorders and Parkinson's disease. Some notable competitors include Biogen Inc., Acorda Therapeutics Inc., and Adamas Pharmaceuticals Inc. These companies also strive to provide innovative treatment options for patients suffering from similar conditions. IRLAB Therapeutics AB differentiates itself by its unique investigational drug, IRL790, which has shown promising results in clinical trials for Parkinson's disease treatment.

IRLAB Therapeutics AB is primarily active in the pharmaceutical industry.

IRLAB Therapeutics AB is a pharmaceutical company with a focus on developing novel treatments for Parkinson's disease and other central nervous system disorders. Their business model centers around research, development, and commercialization of drug candidates that target specific parts of the brain. By leveraging their expertise in drug discovery, IRLAB aims to improve the lives of patients by providing innovative solutions. With a strong commitment to scientific advancement and collaboration, IRLAB Therapeutics AB aims to establish itself as a leading player in the field of neurodegenerative diseases.

IRLAB Therapeutics P/E suhe on −8,38.

IRLAB Therapeutics KUV on 6,00.

AlleAktien kvaliteediskoor ettevõttele IRLAB Therapeutics on 3/10.

oodatud IRLAB Therapeutics käive on 123,62 mln. SEK.

oodatud IRLAB Therapeutics kasum on −88,48 mln. SEK.

IRLAB Therapeutics AB is a biopharmaceutical company based in Sweden that specializes in the discovery and development of innovative drugs for neurodegenerative diseases and pain. Its business model is based on the identification of new compounds, preclinical evaluation, and conducting clinical studies to demonstrate their effectiveness and safety. IRLAB's vision is to help patients achieve a better quality of life by developing drugs that are effective in treating diseases such as Parkinson's, Huntington's, Alzheimer's, and pain. The company's research and development activities are divided into different business areas, including academic research and pharmaceutical development. IRLAB's academic research involves collaborating with renowned academic institutions, universities, and private laboratories worldwide. The company is also involved in researching new technologies and methods to develop better drugs and accelerate the process. On the pharmaceutical development level, IRLAB focuses on two main categories of compounds. On one hand, they are developing selective dopamine concentration modifiers (SDMs) that can improve the function of dopamine neurons in Parkinson's patients. On the other hand, they are developing selective catechol-O-methyltransferase inhibitors (COMT inhibitors) that can be used in the treatment of Parkinson's. The company has also developed a pipeline of drugs for Huntington's disease and pain, which are in various stages of clinical development. IRLAB works closely with medical experts and patient groups to ensure that their drugs meet patient needs. Additionally, the company has entered into a licensing agreement for the commercialization of an already approved product for psychiatric disorders. This product, called IRLAB technology, is for the long-term treatment of panic disorders and generalized anxiety disorders. IRLAB's business model also includes strong partnerships with other pharmaceutical companies and institutional investors to mobilize capital for research and development. The company has entered into several partnerships with other companies to advance the development and commercialization of its products. Overall, IRLAB Therapeutics AB's business model is based on developing innovative drugs for serious neurodegenerative diseases and pain. Through collaboration with leading academics and partners, the company has built a strong pipeline of drugs aiming to help patients achieve a better quality of life. IRLAB is committed to continuous exploration of new technologies and methods to improve the drug development process and better meet the needs of patients.

IRLAB Therapeutics maksab dividendi 0 SEK, mis jaotatakse väljamakse peale aasta jooksul.

Dividendi ei saa praegu IRLAB Therapeutics jaoks arvutada või ettevõte ei maksa dividende välja.

IRLAB Therapeutics ISIN on SE0012675361.

IRLAB Therapeutics WKN on A2PLBE.

IRLAB Therapeutics tähis on IRLAB A.ST.

Viimase 12 kuu jooksul maksis IRLAB Therapeutics dividendi suuruses . See vastab ligikaudu dividenditootlusele. Järgneva 12 kuu jooksul maksab IRLAB Therapeutics tõenäoliselt dividendi summas 0 SEK.

IRLAB Therapeutics praegune dividenditootlus on .

IRLAB Therapeutics maksab kvartaalset dividendi. See makstakse välja kuudel .

IRLAB Therapeutics maksis viimase 0 aasta jooksul igal aastal dividendi.

Järgmise 12 kuu jooksul oodatakse dividende summas 0 SEK. See vastab dividenditootlusele 0 %.

IRLAB Therapeutics on liigitatud sektorisse 'Tervis'.

Viimase IRLAB Therapeutics dividendide saamiseks 28.8.2024 suuruses 0 SEK pidid sul olema aktsiaid portfellis enne eks-dividendi päeva 28.8.2024.

Viimane dividendimakse toimus 28.8.2024.

Aastal 2023 maksis IRLAB Therapeutics 0 SEK dividende.

IRLAB Therapeutics dividendid makstakse välja SEK.